Continuously Advancing New Technologies
At ResourcePath, we are committed to continuously advancing new technologies and approaches to bring cutting-edge solutions to the clinic. Our research spans infectious disease, and oncology, with a particular focus on rare diseases. We have received multiple NIH grants, including R01 and SBIR awards, to support the development and validation of innovative diagnostic tools. Our collaborations with industry, academia, and government agencies enable us to push boundaries and rapidly translate discoveries into clinical practice. We apply the same technologies and expertise to support the needs of our clients.
Upcoming Research & Research Under Review
R21 Grant Submitted & Under Review
Advancing diagnostic testing for Long COVID.
The primary goal of this project is to develop a biomarker blood test for COVID viremia in patients with Long COVID.
Role: Principal Investigator
St. Baldrick’s Award
Advanced Mutiplex Real-time PCR Assays for the Sensitive Detection of Somatic Mutations in Pediatric Malignant Midline Gliomas, K27M Variant
Role: Subcontracted with Rutgers University
Ongoing Research
NIH R01CA2449401
Detecting DICER1: A Global Partnership to Cure Pediatric Lung Cancer
This project, subcontracted with Children’s Minnesota, aims to support clinical utility and validation studies for the DICER-Dx liquid biopsy. The goal is to develop a robust diagnostic tool for early detection of DICER1-related cancers in children, part of the broader Academic-Industry Partnership initiative.
Role: Co-Investigator
NIAID Contract 75N93023D00018
Provides critical support for product development, addressing key gaps in the development of vaccines, diagnostics, and therapeutics. The goal is to accelerate the transition from discovery to clinical development for a wide range of infectious diseases, helping to mitigate emerging health threats by ensuring rapid and safe progression through the product development pipeline.
Role: Task Area E Service Provider (NGS, ELISA, PCR)
Completed Research
NIH/NCI 2 R44 CA228850-02 (2019–2021)
DICER-Dx: The First Liquid Biopsy for Early Detection and Monitoring of DICER1 Syndrome Pediatric Cancers
This project optimized and clinically validated the DICER-Dx assay—a digital droplet PCR test to detect circulating tumor DNA (ctDNA) with DICER1 hotspot mutations. It was part of an international clinical trial for pleuropulmonary blastoma (PPB) in children.
Role: Principal Investigator
NIH/NCI 2R01CA143167-09 (2010–2021)
Pleuropulmonary Blastoma and the DICER1 Family Cancer Syndrome
The goal of this study was to explore the genetic basis of DICER1-related pediatric tumors, including PPB, and develop strategies for early detection and treatment of these rare cancers.
Role: Principal Investigator
